ClinicalTrials.gg
CompletedNCT03824093Updated Jan 20, 2021

High and Low Resource Interventions to Promote HPV Vaccines

An interventional study of AFIX Only and AFIX+ Provider Communication Training in Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination and Meningitis, Meningococcal, sponsored by Children's Mercy Hospital Kansas City. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-20.

Sponsored by Children's Mercy Hospital Kansas City · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2018, registered Jan 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Diphtheria with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Diphtheria · United States.

Enrollment
35th of 43
225 · median 1,045
Started
2018
with 1 other
No phase
3 of 47
none open now
Registered
38th of 47
by date
Lead sponsor
1 of 47
Children's Mercy Hospital Kansas City

Among the 47 studies in Diphtheria with a site in United States, this one is the 35th largest by enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 with no phase, and was the 38th registered.

Diphtheria

268 studies on the registry are indexed under Diphtheria; 18 are open to participants now.

Browse Diphtheria studies →

Open to participants now

1 of the 47 studies in Diphtheria with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Diphtheria with a site in United States, or all of them as a file.
02

Study summary

Human Papillomavirus (HPV) is a significant public health issue affecting nearly 14 million people in the United States. HPV can lead to cervical, oropharyngeal, anal, and penile cancers as well as genital warts.The purpose of this study is to test the comparative effectiveness of two interventions, AFIX only vs. AFIX + communication training, to increase Human Papillomavirus (HPV) vaccination rates among adolescent patients in outpatient clinic settings. Providers and staff at four pediatric practices will be randomized to receive an in-person AFIX consultation or an AFIX consultation combined with communication training and commitment poster displays. Provider and parent data will be collected via a tablet computer RedCap survey. Additional practice and provider level HPV vaccination rates will be collected via patient de-identified claims data. The results of this study could contribute to the existing body of literature that suggests provider recommendations and routine vaccination assessments are key to increasing HPV vaccination uptake. This project has the potential to lead to the implementation and dissemination of low resource interventions to increase HPV vaccination rates among children and adolescents.

Read the detailed description

Significance: Human Papillomavirus (HPV) is the most common sexually transmitted infection in the United States with an estimated 14 million new infections each year. While most HPV infections resolve without any symptoms or signs of infection, some HPV infections can lead to genital warts and cancer. Every year, more than 30,000 people are affected by an HPV-related cancer, including cervical, oropharyngeal, vaginal and anal cancers. Because most adults will become infected with HPV at some point in their lives, the CDC recommends routine vaccination for girls aged 11-26 and boys aged 11-21. While vaccines to prevent HPV infection have been widely available for more than a decade nearly 38% of eligible girls and 50% of eligible boys have not initiated the HPV vaccine series and more than 70% of boys and 50% of girls have not completed the full vaccine series. Rates of HPV vaccination are significantly lower than rates for other adolescent recommended vaccines including, tetanus, diptheria, and acellular pertussis (Tdap), and meningococcal conjugate (MenACWY), which range from 81 to 86 percent. There are many factors that contribute to less than optimal HPV vaccination rates but chief among them is lack of a strong provider recommendation to initiate and complete the HPV vaccine series.

Innovation: This study will be the first randomized controlled trial comparing the effectiveness of an AFIX intervention vs. an AFIX intervention combined with a provider "nudge" that includes a brief communication skills training and commitment messaging displays to increase HPV vaccination rates in pediatric outpatient settings.

Approach: 200 eligible parents (or caregivers) of adolescents between the ages of 11 and 18 will be enrolled and exposed to one of the interventions based on their clinic location. Parents will be recruited from the Children's Mercy Hospital Primary Care Clinic (CMH PCC) and Cradle Thru College Care Pediatrics in Kansas City, MO, Preferred Pediatrics in Lee's Summit, MO, and Cass County Pediatrics in Belton,MO. Practices will be randomized to receive either an in-person AFIX assessment or an in-person AFIX assessment combined with a brief, provider communication training and adolescent vaccine commitment poster displays. The primary outcome of this study is HPV vaccination rates. A secondary outcome is parent ratings of satisfaction with their child's visit with the health care provider. Data will be collected via a tablet computer administered RedCap survey in the exam room immediately following the child's visit.

Public Health Impact: This study could have a significant public health impact and contribute to meeting the Healthy People 2020 goals to reduce vaccine preventable infections by increasing vaccination rates in the pediatric population.

03

Conditions studied

  • Human Papilloma Virus
  • Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination
  • Meningitis, Meningococcal
  • Communication
  • Satisfaction

Keywords

  • Adolescent Vaccines
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parent or legal guardian of a child 11-18 years of age or a pediatric health care provider
  • Parent or legal guardian of a child being seen for a well-child visit
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Prior participation in the study
  • Unable to read or understand English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
225 participants (actual)

Study arms

  • Active comparator
    AFIX Only

    Practices enrolled in the AFIX only arm will receive an in-person AFIX consultation that includes assessment of current HPV vaccination rates and feedback on strategies to increase vaccination rates.

    Behavioral: AFIX Only

  • Active comparator
    AFIX+ Provider Communication Training

    Practices enrolled in the AFIX+ Provider Training arm will receive an in-person AFIX consultation along with a brief communication training for providers and poster and brochure displays in clinic waiting and exam rooms.

    Behavioral: AFIX+ Provider Communication Training

Interventions

  • BehavioralAFIX Only

    The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates.

  • BehavioralAFIX+ Provider Communication Training

    The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates along with communication training for providers and poster and brochure displays.

06

What researchers measure

Primary outcomes

  1. HPV vaccination rates

    Practice and provider level HPV vaccination rates will be collected from patient de-identified claims data.

    Time frame: 18 months

Secondary outcomes

  1. Parent Satisfaction

    Parent satisfaction with visit will be collected using validated measures on tablet computers

    Time frame: 18 months

07

Study locations

1 site
  • Children's Mercy Hospital Kansas City
    Kansas City, Missouri 64108, United States
08

References and documents

Individual participant data

Plan to share: Yes — We will create a clean, de-identified copy of our final dataset that will be available to other researcher groups, upon request, within 9 months of the end of the study period. Prior to data sharing, we will remove all identifying information. We will make data and associated documentation available to users under a data-sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be made available 9 months after the conclusion of the study upon request and completion of a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in May 2020, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2019
First posted
Jan 31, 2019
StartActual
Jul 1, 2018
Primary completionActual
May 6, 2020
CompletionActual
May 6, 2020
Last update
Jan 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03824093
Collaborators
University of Kansas Medical Center, Midwest Cancer Alliance
Responsible party
Sponsor
First posted
Jan 31, 2019
Start date
Jul 1, 2018
Primary completion
May 6, 2020
Completion
May 6, 2020
Last update
Jan 20, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion